The effect of the “Joining Uncertainty Management & Meaning Making Program” to promote patient-centered care in hematopoietic stem cell transplantation

ISRCTN ISRCTN20578668
DOI https://doi.org/10.1186/ISRCTN20578668
Secondary identifying numbers 20191128
Submission date
23/02/2025
Registration date
20/04/2025
Last edited
27/02/2025
Recruitment status
No longer recruiting
Overall study status
Ongoing
Condition category
Other
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
The study team have developed and implemented an uncertainty-management program based on meaning-making and evaluated the effect of the program on uncertainty, personal growth, healthcare empowerment, and self-efficacy.

Who can participate?
Patients undergoing hematopoietic stem cell transplantation aged between 18 and 69 years old

What does the study involve?
The intervention program included seven sessions. In the first session, participants learned how to use a smartphone app to check their blood count and scan QR codes. They were given help to install the app and shown how to use it. Throughout the program, they received ongoing education and support through phone calls or face-to-face meetings. The team also checked if participants were using the educational materials and provided extra help if needed. Regular phone calls were made to answer any questions and support them through the transplant process.

What are the possible benefits and risks of participating?
This study is expected to contribute to the literature by showing that interacting with medical professionals and receiving information and education at the patient’s level of understanding and treatment condition effectively decreases uncertainty and helps them find meaning in a difficult journey.

This study is not an intervention involving medication or treatment, but rather counseling and education with patients, so participation is not expected to cause harm. However, the consent form states that if the patient withdraws consent or wishes to discontinue it, he or she may express his/her intention.

Where is the study run from?
The study is hospital-based at the Asan Medical Center, South Korea, but interaction will occur at any time when participants need help.

When is the study starting and how long is it expected to run for?
January 2019 to December 2025

Who is funding the study?
Asan Medical Center, South Korea

Who is the main contact?
Mrs Young-shin Lee, lysinkorea@amc.seoul.kr, lysinkorea@gmail.com

Contact information

Mrs Young-Shin Lee
Public, Scientific, Principal Investigator

Asan Medical Center, 88, Olympic-RO 43-GIL, Songpa-Gu
Seoul
05505
Korea, South

ORCiD logoORCID ID 0000-0001-8204-7838
Phone +82-10-4402-7528
Email lysinkorea@amc.seoul.kr

Study information

Study designNonequivalent control group non-synchronized quasi-experimental design
Primary study designInterventional
Secondary study designNon randomised study
Study setting(s)Hospital, Internet/virtual, Telephone
Study typeSafety, Efficacy
Participant information sheet 46887_PIS_Case Report Form.pdf
Scientific titleDevelopment and evaluation of joining uncertainty management & meaning making program for hematopoietic stem cell transplantation patients
Study objectivesHypothesis 1: The level of uncertainty in the experimental group, who participated in the uncertainty-management program based on meaning-making, will become distinctively different over time from that of the control group.
Hypothesis 2: Compared to the control group, the level of personal growth will be higher in the experimental group, who participated in the uncertainty-management program based on meaning-making.
Ethics approval(s)

Approved 28/11/2019, IRB committee, Asan Medical Center (88, Olympic-RO 43-GIL, Songpa-Gu, Seoul, 05505, Korea, South; +82-2-3010-7166; irb@amc.seoul.kr), ref: S2019-2341-0002

Health condition(s) or problem(s) studiedMeaning-making to an intervention program for managing the uncertainty of patients undergoing HSCT
InterventionBased on previous study findings, an intervention program was constructed comprising seven sessions. Session 1 took about 30 minutes. To begin the JUM3P, participants had to understand how to check their blood count using a smartphone app and how to scan a QR code. Thus, about 20 minutes were spent helping install the program and checking to see if patients could use the tool on their own. In addition, a demonstration was given when patients had difficulty understanding. From then on, patients were continuously educated and provided consultation through phone calls or face-to-face interviews regarding their areas of concern. It was also checked whether they had looked at the educational content using the QR codes. Those who had forgotten how to use the QR codes were re-educated and given verbal additional information in an orderly fashion. The network with the patients was maintained by visiting with them via phone calls when it was expected they would have questions or a hard time coping with the transplant process.
Intervention typeBehavioural
Primary outcome measureThe following primary outcome measures are assessed at T1 (baseline at enrollment), T2 (before conditioning regimen for HSCT), and T3 (one week after discharge):
1. Uncertainty measured using the Mishel-Uncertainty of Illness Scale (MUIS)
2. Personal growth measured using the Growth through Uncertainty Scale (GTUS)
3. Healthcare competency measured using the Health Care Empowerment Inventory (HCEI)
4. Self-efficacy measured using the General Self-Efficacy Scale (GSE)
Secondary outcome measuresThere are no secondary outcome measures
Overall study start date01/01/2019
Completion date31/12/2025

Eligibility

Participant type(s)Patient
Age groupMixed
Lower age limit18 Years
Upper age limit69 Years
SexBoth
Target number of participants54
Total final enrolment35
Key inclusion criteria1. In-patients undergoing allogeneic HSCT for the first time after being diagnosed with a blood disorder
2. In-patients and out-patients preparing for allogeneic HSCT
3. Men or women between the ages of 18 and 69 years
Key exclusion criteria1. A person with a psychiatric history or currently receiving treatment for a psychiatric disorder
2. A person undergoing emergency HSCT
3. A person needing a caregiver’s help due to a weakened physical condition at the time of recruiting the research participants
Date of first enrolment28/11/2019
Date of final enrolment02/11/2021

Locations

Countries of recruitment

  • Korea, South

Study participating centre

Asan Medical Center
88, Olympic-RO 43-GIL, Songpa-Gu
Seoul
05505
Korea, South

Sponsor information

Asan Medical Center
Hospital/treatment centre

Hematology Department, 88, Olympic-RO 43-GIL, Songpa-Gu
Seoul
05505
Korea, South

Phone +82 82-2-3010-3292
Email choiysmd@amc.seoul.kr
Website https://eng.amc.seoul.kr/gb/lang/specialities/departments.do?hpCd=D012

Funders

Funder type

Hospital/treatment centre

Asan Medical Center

No information available

Results and Publications

Intention to publish date01/03/2025
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planPlanned publication in a peer reviewed journal
IPD sharing planThe datasets generated during and/or analysed during the current study are/will be available upon request from Young-shin Lee, lysinkorea@amc.seoul.kr, lysinkorea@gmail.com. Participants were notified that their information would be kept confidential and would not be used for any other purpose except for the research.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Participant information sheet 25/02/2025 No Yes

Additional files

46887_PIS_Case Report Form.pdf

Editorial Notes

25/02/2025: Study's existence confirmed by IRB committee, Asan Medical Center.